Evidence map›Paper›PMID 34614289›Full record

ArticleAdvanced healthcare materials2022

An Outer Membrane Vesicle-Based Permeation Assay (OMPA) for Assessing Bacterial Bioavailability.

Robert Richter, Mohamed A M Kamal, Marcus Koch, Bart-Jan Niebuur, Anna-Lena Huber, Adriely Goes, Carsten Volz, Julia Vergalli, Tobias Kraus, Rolf Müller and 4 more

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Proteomic Profiling of Outer Membrane Vesicles Released byJournal of personalized medicine · 2022
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Robert RichterHelmholtz Centre for Infection Research, Helmholtz Institute for Pharmaceutical Research Saarland, Campus E8.1, Saarbrücken, 66123, Germany.ORCID 0000-0002-3828-9773
Mohamed A M KamalHelmholtz Centre for Infection Research, Helmholtz Institute for Pharmaceutical Research Saarland, Campus E8.1, Saarbrücken, 66123, Germany.ORCID 0000-0001-7095-1993
Marcus KochINM - Leibniz Institute for New Materials, Campus D2.2, Saarbrücken, 66123, Germany.
Bart-Jan NiebuurINM - Leibniz Institute for New Materials, Campus D2.2, Saarbrücken, 66123, Germany.
Anna-Lena HuberHelmholtz Centre for Infection Research, Helmholtz Institute for Pharmaceutical Research Saarland, Campus E8.1, Saarbrücken, 66123, Germany.
Adriely GoesHelmholtz Centre for Infection Research, Helmholtz Institute for Pharmaceutical Research Saarland, Campus E8.1, Saarbrücken, 66123, Germany.ORCID 0000-0003-2629-6068
Carsten VolzHelmholtz Centre for Infection Research, Helmholtz Institute for Pharmaceutical Research Saarland, Campus E8.1, Saarbrücken, 66123, Germany.ORCID 0000-0001-7094-5294
Julia VergalliUMR_MD1, U-1261, Aix-Marseille Université, INSERM, IRBA, MCT, Faculté de Pharmacie, 27 Boulevard Jean Moulin, Marseille, 13005, France.ORCID 0000-0003-3253-6275
Tobias KrausINM - Leibniz Institute for New Materials, Campus D2.2, Saarbrücken, 66123, Germany.ORCID 0000-0003-2951-1704
Rolf MüllerHelmholtz Centre for Infection Research, Helmholtz Institute for Pharmaceutical Research Saarland, Campus E8.1, Saarbrücken, 66123, Germany.ORCID 0000-0002-1042-5665
Nicole Schneider-DaumHelmholtz Centre for Infection Research, Helmholtz Institute for Pharmaceutical Research Saarland, Campus E8.1, Saarbrücken, 66123, Germany.ORCID 0000-0001-9319-2010
Gregor FuhrmannHelmholtz Centre for Infection Research, Helmholtz Institute for Pharmaceutical Research Saarland, Campus E8.1, Saarbrücken, 66123, Germany.ORCID 0000-0002-6688-5126
Jean-Marie PagèsUMR_MD1, U-1261, Aix-Marseille Université, INSERM, IRBA, MCT, Faculté de Pharmacie, 27 Boulevard Jean Moulin, Marseille, 13005, France.ORCID 0000-0001-7092-7977
Claus-Michael LehrHelmholtz Centre for Infection Research, Helmholtz Institute for Pharmaceutical Research Saarland, Campus E8.1, Saarbrücken, 66123, Germany.ORCID 0000-0002-5864-8462

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

When searching for new antibiotics against Gram-negative bacterial infections, a better understanding of the permeability across the cell envelope and tools to discriminate high from low bacterial bioavailability compounds are urgently needed. Inspired by the phospholipid vesicle-based permeation assay (PVPA), which is designed to predict non-facilitated permeation across phospholipid membranes, outer membrane vesicles (OMVs) of Escherichia coli either enriched or deficient of porins are employed to coat filter supports for predicting drug uptake across the complex cell envelope. OMVs and the obtained in vitro model are structurally and functionally characterized using cryo-TEM, SEM, CLSM, SAXS, and light scattering techniques. In vitro permeability, obtained from the membrane model for a set of nine antibiotics, correlates with reported in bacterio accumulation data and allows to discriminate high from low accumulating antibiotics. In contrast, the correlation of the same data set generated by liposome-based comparator membranes is poor. This better correlation of the OMV-derived membranes points to the importance of hydrophilic membrane components, such as lipopolysaccharides and porins, since those features are lacking in liposomal comparator membranes. This approach can offer in the future a high throughput screening tool with high predictive capacity or can help to identify compound- and bacteria-specific passive uptake pathways.

Indexed as

Gram-Negative BacteriaPorinsBiological AvailabilityScattering, Small AngleX-Ray DiffractionPorinsantimicrobial resistancebacterial bioavailabilitydrug optimizationextracellular vesiclesin vitro studiesmembrane permeation models

Identifiers

PMID34614289
PMCPMC11468809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.